Information  X 
Enter a valid email address

Faron Pharma OY Ord NPV (DI) (FARN)

Date Time Source Announcement
12 Jul 2019 7:00 am
RNS
MATINS study update
05 Jul 2019 9:00 am
RNS
Price Monitoring Extension
04 Jul 2019 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  2:00 pm
RNS
Price Monitoring Extension
  9:31 am
RNS
Holdings in Company
01 Jul 2019 12:10 pm
RNS
Grant of options
26 Jun 2019 7:00 am
RNS
Phase II INFORAAA study update
14 Jun 2019 7:00 am
RNS
Final results from YODA study
28 May 2019 12:27 pm
RNS
Results of AGM
24 May 2019 9:32 am
RNS
AGM update, Board & management changes
22 May 2019 12:51 pm
RNS
Grant of Options
21 May 2019 9:21 am
RNS
Holding(s) in Company
16 May 2019 9:16 am
RNS
Holding(s) in Company
  9:16 am
RNS
Holding(s) in Company
14 May 2019 7:01 am
RNS
Holdings in Company
  7:00 am
RNS
Share Subscription and Issue of Equity
07 May 2019 7:05 am
RNS
Notice of AGM
  7:00 am
RNS
Final Results for the year ended 31 December 2018
02 May 2019 5:20 pm
RNS
Statement regarding Price Movement
  2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
29 Apr 2019 7:00 am
RNS
Results from the Japanese Phase III study
25 Apr 2019 4:09 pm
RNS
Holding(s) in Company
12 Apr 2019 1:20 pm
RNS
Holding(s) in Company
11 Apr 2019 7:00 am
RNS
First expansion cohort for MATINS trial part 2
10 Apr 2019 11:41 am
RNS
Holding(s) in Company
05 Apr 2019 7:00 am
RNS
Notice of Results
02 Apr 2019 9:23 am
RNS
Holdings in Company
  9:23 am
RNS
Holdings in Company
29 Mar 2019 7:00 am
RNS
Holding(s) in Company
28 Mar 2019 12:54 pm
RNS
Results of the Placing and Subscription
26 Mar 2019 3:31 pm
RNS
Result of Placing and Issue Price
  7:00 am
RNS
Proposed Placing to raise approximately EUR 3m
21 Feb 2019 7:00 am
RNS
MATINS study update
13 Feb 2019 8:57 am
RNS
New data published by Clinical Cancer Research
19 Dec 2018 7:00 am
RNS
Traumakine update - YODA results
14 Dec 2018 11:20 am
RNS
First patient dosed in phase I/II MATINS study
11 Dec 2018 4:26 pm
RNS
Holding(s) in Company
05 Dec 2018 7:00 am
RNS
Patient subgroup identified from INTEREST trial
03 Dec 2018 7:00 am
RNS
Faron receives CTA approval for Clevegen
06 Nov 2018 3:52 pm
RNS
PDMR Dealings
23 Oct 2018 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  9:06 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
22 Oct 2018 3:00 pm
RNS
INTEREST trial update presented at ESICM
18 Sep 2018 9:23 am
RNS
Director/PDMR Shareholding
17 Sep 2018 7:00 am
RNS
Faron announces CTA filing for Clevegen
13 Sep 2018 7:00 am
RNS
Interim Results
12 Sep 2018 7:00 am
RNS
New data published on Clever-1 function
08 Aug 2018 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Notice of Interim Results
09 Jul 2018 8:45 am
RNS
Holding(s) in Company
28 Jun 2018 7:00 am
RNS
Clevegen successful toxicity studies
22 Jun 2018 7:00 am
RNS
Holdings in Company
  7:00 am
RNS
Holdings in Company
21 Jun 2018 3:58 pm
RNS
Director/PDMR Shareholding
  9:00 am
RNS
Price Monitoring Extension
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t